Journal of Clinical Oncology
Articles in this Issue
Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma.
11505 Background: Afamitresgene autoleucel (afami-cel) is a melanoma-associated antigen A4 (MAGEA4)-directed genetically m...
Trends in HIV, hepatitis B, and hepatitis C eligibility language in immune checkpoint inhibitor oncology trials: A ClinicalTrials.gov rule-based NLP analysis (2010–2025).
e23011 Background: Exclusion of people with HIV or viral hepatitis can limit generalizability of immune checkpoint inhibit...
Trends in mortality among older adults with coexisting ischemic heart disease and thoracic malignancies: A 25-year analysis of U.S. national data.
e24029 Background: Ischemic heart disease (IHD) and thoracic malignancies are leading causes of death in older adults, oft...
Impact of pre-existing autoimmune disease on outcomes of immune checkpoint inhibitors in non–small cell lung cancer: A real-world multi-institutional cohort study.
e20612 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have become a cornerstone of trea...
Nivolumab plus ipilimumab with chemotherapy as first-line therapy for NSCLC: A single-center real-world experience.
e20630 Background: Dual immune checkpoint inhibition combined with platinum-based chemotherapy has become one of the stand...
Safety of glucagon-like peptide-1 receptor agonists in patients with breast cancer: A real-world multicenter cohort study.
11139 Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for patients with breas...
Prediction of anthracycline-related cardiomyopathy in long-term childhood cancer survivors: The power of survivor-specific polygenic risk score—A COG-ALTE03N1 study.
10005 Background: Cardiomyopathy is a major dose-limiting toxicity of anthracyclines in the treatment of childhood cancer....
Popliteal node metastasis in infra-popliteal melanoma: Arcane or mundane?
e21594 Background: Infra-popliteal melanoma constitutes a major percentage of cutaneous melanoma among women. The primary...
Real-world clinicopathologic features and outcomes of gastric, esophageal, and gastroesophageal junction cancers: A single-center cohort study.
e16057 Background: Upper gastrointestinal cancers encompass biologically and clinically distinct entities with evolving ma...
Intraoperative indocyanine green fluorescence angiography to reduce anastomotic leak after esophagectomy for esophageal cancer: A systematic review and meta-analysis.
e16097 Background: Anastomotic leak remains one of the most serious complications following esophagectomy for esophageal c...
Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab.
4569 Background: Enfortumab vedotin plus pembrolizumab (EV±P) is standard-of-care for patients (pts) with locally advanced...
Real-world outcomes of urothelial bladder cancer (UBC): A retrospective multicenter analysis from Peru.
e23433 Background: Urothelial bladder cancer (UBC) outcomes in Latin America remain poorly characterized. Although inciden...
Post-treatment pathway profiling and platinum resistance in high-grade serous ovarian cancer: Discovery and external validation study.
e17602 Background: High-grade serous ovarian cancer (HGSOC) shows initial platinum sensitivity in >70% of patients, but...
Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
4508 Background: Enfortumab vedotin plus pembrolizumab (EVP) is the current first-line standard of care for locally advanc...
A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.
e15156 Background: Conventional alkylating agents are limited by systemic toxicities and lack of selectivity. LP-184 is a...
Trends in female breast cancer incidence and mortality in adolescents and young adults in Sub-Saharan Africa from 1990 to 2023.
e22585 Background: Breast cancer (BC) among adolescent and young adults (AYA), defined as individuals aged 15 to 39 years,...
Lung cancer screening practices among head and neck cancer survivors in U.S. veterans: A pilot survey.
e23148 Background: Survivors of head and neck (HNC) cancers constitute a uniquely high-risk population for second primary...
Integrating clinicopathologic factors and immune repertoire sequencing to optimize decision-making in neoadjuvant chemoimmunotherapy for HNSCC: A pooled analysis.
e18065 Background: Neoadjuvant chemoimmunotherapy (NACIT) improves survival in locally advanced head and neck squamous cel...
Surgical de-escalation of implant-based breast reconstruction (IBBR) after mastectomy for breast cancer treatment or prevention: The international randomized phase III PREPEC trial (OPBC-02).
504 Background: The optimal positioning of implants following skin- (SSM) or nipple-sparing mastectomy (NSM) for breast ca...
Real-world evidence on the influence of node positivity and advanced clinical stage on response and survival after CROSS regimen in esophageal/GEJ cancer.
e16103 Background: The CROSS regimen (weekly carboplatin/paclitaxel with concurrent radiation) improves outcomes in resect...
Detecting <i>MTAP</i> loss in liquid biopsies from patients with clinically advanced colorectal cancer (CRC).
3553 Background: Homozygous loss of the MTAP gene ( MTAP...
Patterns and determinants of radiotherapy treatment default in a rural cancer centre: A retrospective observational study.
11175 Background: Radiotherapy requires uninterrupted daily treatment over several weeks, making treatment adherence chall...
The mitochondrial apoptosis profile in meningiomas and gliomas: Comparing the effects of patient sex, tumor histology, and grade.
e14063 Background: Gliomas and meningiomas are the most common malignant (primary) and benign brain tumors, respectively....
Phase II study of T-Bren (BL-M07D1) monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer.
1049 Background: T-Bren is a HER2-directed antibody-drug conjugate (ADC) consisting of an anti-HER2 monoclonal antibody li...
A phase II open-label, single-arm study to evaluate the efficacy of pembrolizumab for leukoplakia.
10544 Background: Oral leukoplakia and erythroleukoplakia represent high-risk premalignant lesions of the oral cavity, wit...